Page last updated: 2024-12-11

collinin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

collinin: the active principle of Zanthoxylum spp.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
ZanthoxylumgenusA plant genus of the family RUTACEAE. Some members of Zanthoxylum are reclassified from ELEUTHEROCOCCUS, Melicope, and EVODIA. The twigs are used as dental brushing sticks (TOOTHBRUSHING). Most plants that are called Fagara have been reclassified as Zanthoxylum, however some Fagara were reclassified to MELICOPE (also in the Rutacea family) or to GLEDITSIA (a genus in the FABACEAE family).[MeSH]RutaceaeA plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH]

Cross-References

ID SourceID
PubMed CID5316012
CHEMBL ID306908
MeSH IDM0528003

Synonyms (11)

Synonym
34465-83-3
NSC31870 ,
collinin
nsc-31870
CHEMBL306908
7-[(2e)-3,7-dimethylocta-2,6-dienoxy]-8-methoxychromen-2-one
7-[[(2e)-3,7-dimethyl-2,6-octadien-1-yl]oxy]-8-methoxy-2h-1-benzopyran-2-one
CS-0143841
HY-N8388
(e)-7-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-8-methoxy-2h-chromen-2-one
AKOS040756361

Research Excerpts

Overview

Collinin is a secondary plant metabolite belonging to the class of geranyloxycoumarins. It is isolated in small amounts from plants of the Rutaceae family.

ExcerptReferenceRelevance
"Collinin is a geranyloxycoumarins isolated in small amounts from plants of the Rutaceae family. "( Chemistry and pharmacology of collinin, active principle of Zanthoxylum spp.
Curini, M; Epifano, F; Genovese, S; Marcotullio, MC, 2008
)
2.08
"Collinin is a secondary plant metabolite belonging to the class of geranyloxycoumarins. "( Collinin reduces Porphyromonas gingivalis growth and collagenase activity and inhibits the lipopolysaccharide-induced macrophage inflammatory response and osteoclast differentiation and function.
Curini, M; Epifano, F; Genovese, S; Grenier, D; Marquis, A; Santos, J, 2013
)
3.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1359333Induction of melanogenesis in mouse Melan-a cells assessed as effect on tanning property at 40 uM after 48 hrs2018European journal of medicinal chemistry, May-25, Volume: 152Natural oxyprenylated coumarins are modulators of melanogenesis.
AID306626Inhibition of FTase at 100 uM2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I.
AID449576Anticonvulsant activity in mouse at 300 mg/kg, ip after 120 mins by MES test2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Prenyloxyphenylpropanoids as a novel class of anticonvulsive agents.
AID659716Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 100 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID117727Percent uM/cm**22004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Synthesis and anti-inflammatory activity of natural and semisynthetic geranyloxycoumarins.
AID110864Inhibitory activity against mouse uM/cm**2 (control=7.0)2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Synthesis and anti-inflammatory activity of natural and semisynthetic geranyloxycoumarins.
AID659712Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 5 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID659711Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 1 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID659717Agonist activity at human farnesoid X receptor expressed in human HepG2 cells after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID659715Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 50 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID1359332Cytotoxicity against mouse Melan-a cells assessed as effect on cell viability at <2 uM after 24 to 72 hrs by trypan blue exclusion assay2018European journal of medicinal chemistry, May-25, Volume: 152Natural oxyprenylated coumarins are modulators of melanogenesis.
AID306627Inhibition of GGTase 1 at 100 uM2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I.
AID659713Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 10 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID1359334Inhibition of melanogenesis in mouse Melan-a cells assessed as effect on whitening property at 40 uM after 48 hrs2018European journal of medicinal chemistry, May-25, Volume: 152Natural oxyprenylated coumarins are modulators of melanogenesis.
AID659714Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 25 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID659710Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 0.1 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID449574Anticonvulsant activity in mouse at 300 mg/kg, ip after 30 mins by MES test2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Prenyloxyphenylpropanoids as a novel class of anticonvulsive agents.
AID1357276Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production2018European journal of medicinal chemistry, Jun-10, Volume: 153Recent acquisitions on oxyprenylated secondary metabolites as anti-inflammatory agents.
AID449573Anticonvulsant activity in mouse at 300 mg/kg, ip after 15 mins by MES test2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Prenyloxyphenylpropanoids as a novel class of anticonvulsive agents.
AID449575Anticonvulsant activity in mouse at 300 mg/kg, ip after 60 mins by MES test2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Prenyloxyphenylpropanoids as a novel class of anticonvulsive agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (45.45)29.6817
2010's5 (45.45)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.71 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (18.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]